PTO/SB/088 (09-06)
Approved for use through 03/01/2007, OM8 0651-0031
U.S. Parent and Trademark Office; U.S. OEPARTMENT OF COMMERCE

Under the Pagework Reduction Act of 1995, no paraons are required to respond to a collection of information unless it contains a wild OMB control runtl

Complete If Known Substitute for form 1449/PTO

Application Number 10/568,292 INFORMATION DISCLOSURE Filing Date August 14, 2006 (371(c) Date) STATEMENT BY APPLICANT First Named Invento Benny Bang-Andersen, et al. Art Unit 1624 (Use as many sheets as necessary) Examiner Name Emily B. Bernherdt Attorney Docket Number 463-US-PCT of 2

NON PATENT LITERATURE DOCUMENTS Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of T² the item (book, megazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published HALEBLIAN, JOHN, et al., "Pharmaceutical Applications of Polymorphism", Journal of Pharmaceutical Sciences, August 1969, pp. 911-929, Vol. 58, No. 8. DAVIES, Huw M. L., et al., "Asymmetric Synthesis of (+)-Indatraline Using Rhodium-Catalyzed C-H Activation", Tetrahedron Letters, 2002, pp. 4951-4953, 43, Pergamon.

Examiner			Date Considered		

FIXABLER Initial freference considered, whether or not obtain is conformance with MPSP 509. Day in a through district in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Nativals copy of the form with not communication to applicate.

"Applicated space, of the form with not communication to applicate the plants and seal control to a PC Explain to page on Transplain or produced in a service of the Communication of the Communication of the Communication or the